Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2024-02-02 00:00:00 ET · period of report 2024-01-31 · accession 0001968202-24-000045 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-02 | 2024-01-31 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $378.98 | +400 | 23.9K | +2% | +$151.6K |
| D | 2024-02-02 | 2024-01-31 | REGN | Landry Robert E | EVP Fin CFO | F - Tax | $953.42 | -282 | 23.6K | -1% | -$268.9K |
| D | 2024-02-02 | 2024-01-31 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $0.00 | -400 | 12.2K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-31 | M | A | 400 | $378.98 | 23,856 | D | — | — | |
| 2 | Common | Common Stock | 2024-01-31 | F | D | 282 | $953.42 | 23,574 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-01-31 | M | D | 400 | $0.00 | 12,187 | D | $378.98 · — to 2027-12-12 | 400 Common Stock | (F1) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |